Celtic Pharma Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (51)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Celtic Pharma - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Celtic Pharma. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drug in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Celtic Pharma - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Celtic Pharma - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Celtic Pharma. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drug in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Celtic Pharma - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Celtic Pharma

  1.1 Business Overview

  1.2 Celtic Pharma Cancer Pipeline Overview

 

2. Celtic Pharma Cancer Drugs in Phase-II

  2.1 Human Papillomavirus Vaccine TA-CIN - Cancer Research Technology

 

3. No Development Reported in Cancer Drugs in Clinical Pipeline

  3.1 Corticorelin

  3.2 XR 5944

 

4. Disconitnued in Cancer Drugs in Clinical Pipeline

  4.1 XR 311

  4.2 Tariquidar

  4.3 Human Papillomavirus Vaccine TA-HPV – Xenova

  4.4 XR 5000

  4.5 XR 303

  4.6 Cancer Vaccine - Xenova/Oxxon

  4.7 XR 11576

  4.8 Anti-CTA Monoclonal Antibodies - Xenova Group

  4.9 XR 9051

  4.10 XR 11612

  4.11 OX40 Based Therapeutics – Genentech

  4.12 Plasminogen Activator Inhibitor-1 Inhibitors – Xenova

  4.13 DISC Gene Delivery – Xenova

  4.14 p53 Function Restorers – Xenova

  4.15 XR 5942

  4.16 M3

  4.17 MRP Inhibitors – Xenova

  4.18 Anti-Cancer Monoclonal Antibodies - Xenova/Aurelium

  4.19 HIF-1 alpha Inhibitors – Xenova

  4.20 Anti-EGFR Monoclonal Antibody KSB 107

  4.21 Bispecific Antibodies for Pretargeting Radioimmunotherapy - Xenova Group

  4.22 Anti-Angiogenesis Monoclonal Antibodies - Xenova Group/Schering AG

  4.23 Telomerase Inhibitors – Xenova

  4.24 Enzyme Linked Antibody Nutrient Depletion Therapy - KS Biomedix Holdings

  4.25 Anti-EGFR Sheep Monoclonal Antibody

  4.26 Anti-TNF Sheep Monoclonal Antibody - KS Biomedix Holdings

  4.27 XR 9211

  4.28 XR 3054

  4.29 XR 9019

  4.30 XR 1500

  4.31 XR 334

  4.32 XR 3005

  4.33 Anti-VEGF Sheep Monoclonal Antibody - KS Biomedix Holdings

  4.34 Anti-PDGF/bFGF Sheep Monoclonal Antibody

  4.35 Anti-Tissue Factor/Factor VIIA Sheep Monoclonal Antibody


Figure 1-3: Celtic Pharma Cancer Clinical pipeline by Phase (%)

Figure 1-4: Celtic Pharma Cancer Clinical pipeline by Phase (Number)